ASTRO 2021: NCCN Guidelines for Radiation Therapy and Prostate Cancer: Updates and Controversies
Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association
Current Oncology | Free Full-Text | A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
Frontiers | Prostate Cancer Theranostics - An Overview
Frontiers | Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches
Cancers | Free Full-Text | Management of Advanced Prostate Cancer in the Precision Oncology Era
Prostate Cancer Treatment & Management: Approach Considerations, Localized Prostate Cancer, Management of Advanced and Metastatic Disease
Treatment of Castration-Resistant Prostate Cancer (CRPC)
Full article: Docetaxel radiosensitizes castration-resistant prostate cancer by downregulating CAV-1
Prostate Cancer - INTRODUCTION - Uroweb
Advances in Prostate Cancer Chemotherapy: A New Era Begins1 - Pienta - 2005 - CA: A Cancer Journal for Clinicians - Wiley Online Library
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial - The Lancet
Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association
Trial profile for Scandinavian Prostate Cancer Group 12: Arm A adjuvant... | Download Scientific Diagram
Salvage therapy for prostate cancer after radical prostatectomy | Nature Reviews Urology
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol - The
Prostate Cancer Treatment (PDQ®) - NCI
Survival Advantage with Frontline Docetaxel in Combination With Hormone Deprivation Therapy in Hormone Sensitive Prostate Cancer | Roswell Park Comprehensive Cancer Center - Buffalo, NY
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases
Cancers | Free Full-Text | Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes
Frontiers | Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023 in: Journal of the National Comprehensive Cancer Network Volume 20 Issue 12 (2022)
How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk: A Therapeutic Tightrope | JACC: CardioOncology
Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation | Anticancer Research
Prostate Cancer - INTRODUCTION - Uroweb
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
